734 related articles for article (PubMed ID: 35031816)
1. Analysis of recreational psychedelic substance use experiences classified by substance.
Hase A; Erdmann M; Limbach V; Hasler G
Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
[TBL] [Abstract][Full Text] [Related]
2. Psychedelics and Psychedelic-Assisted Psychotherapy.
Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
[TBL] [Abstract][Full Text] [Related]
3. The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
Zaretsky TG; Jagodnik KM; Barsic R; Antonio JH; Bonanno PA; MacLeod C; Pierce C; Carney H; Morrison MT; Saylor C; Danias G; Lepow L; Yehuda R
Curr Neuropharmacol; 2024; 22(4):636-735. PubMed ID: 38284341
[TBL] [Abstract][Full Text] [Related]
4. Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying.
Sweeney MM; Nayak S; Hurwitz ES; Mitchell LN; Swift TC; Griffiths RR
PLoS One; 2022; 17(8):e0271926. PubMed ID: 36001643
[TBL] [Abstract][Full Text] [Related]
5. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
[TBL] [Abstract][Full Text] [Related]
6. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
[TBL] [Abstract][Full Text] [Related]
7. Psychedelic drugs-a new era in
psychiatry?
.
Nutt D
Dialogues Clin Neurosci; 2019; 21(2):139-147. PubMed ID: 31636488
[TBL] [Abstract][Full Text] [Related]
8. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
Lyvers M; Meester M
J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
[TBL] [Abstract][Full Text] [Related]
9. Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives.
Cox DJ; Garcia-Romeu A; Johnson MW
Am J Drug Alcohol Abuse; 2021 Jul; 47(4):444-454. PubMed ID: 34096403
[No Abstract] [Full Text] [Related]
10. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
[TBL] [Abstract][Full Text] [Related]
11. The use of classic psychedelics among adults: a Danish online survey study.
Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A
Nord J Psychiatry; 2023 May; 77(4):367-378. PubMed ID: 36173202
[TBL] [Abstract][Full Text] [Related]
12. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
Barnett BS; Parker SE; Weleff J
Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734
[TBL] [Abstract][Full Text] [Related]
13. The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits.
Videira NB; Nair V; Paquet V; Calhoun D
J Appl Toxicol; 2024 Feb; 44(2):216-234. PubMed ID: 37646119
[TBL] [Abstract][Full Text] [Related]
14. Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
Am J Ther; 2024 Mar-Apr 01; 31(2):e97-e103. PubMed ID: 38518266
[TBL] [Abstract][Full Text] [Related]
15. Mystical and Affective Aspects of Psychedelic Use in a Naturalistic Setting: A Linguistic Analysis of Online Experience Reports.
Žuljević MF; Mijatović A; Marušić SL; Kudrjavets G; Buljan I; Hren D
J Psychoactive Drugs; 2023 Nov; ():1-13. PubMed ID: 37921118
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics.
Hovmand OR; Poulsen ED; Arnfred S
J Psychopharmacol; 2024 Jan; 38(1):19-32. PubMed ID: 37969069
[TBL] [Abstract][Full Text] [Related]
17. Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models.
Ezeaka UC; Kim HJJ; Laprairie RB
Curr Top Med Chem; 2023; 23(23):2232-2241. PubMed ID: 37409550
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
[TBL] [Abstract][Full Text] [Related]
19. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
[TBL] [Abstract][Full Text] [Related]
20. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.
Rhee TG; Davoudian PA; Sanacora G; Wilkinson ST
Drug Discov Today; 2023 Dec; 28(12):103818. PubMed ID: 37925136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]